# Sciencare Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sciencare-medical

- Industry: Pharmaceuticals
- Headquarters: Shenzhen, China
- Website: www.sciencare.cn
- Total disclosed funding: $28M
- Latest round: Series B (Aug 26, 2021)
- Investors on record: 8

## About

Based in Shenzhen, China and established in 2017, Sciencare Medical is a drug developer company that focuses on the research and development of innovative drugs with independent intellectual property rights. The predecessor has more than ten years of research and development basis for drug sustained release technology. It's self-developed naltrexone implant was included in the breakthrough therapy product by the Center for Drug Evaluation of the National Medical Products Administration. It has a total area of 8,000 square meters sites in Pingshan District, Shenzhen. It is committed to the independent research and development, production and sales of innovative drugs. It is invested by several funds such as Shenzhen Capital fortune, Shenzhen Capital Group, People's Daily Online.  

It provides long-acting sustained and controlled release drugs. Specific products include a long-acting naltrexone implant, a long-acting sustained-release preparation for drug withdrawal.

## Funding rounds

- Series B, Aug 26, 2021, $28M — CAS Investment Management, Xiaoxiang Capital Group, Shenzhen Capital Real Estate Fund, Huajin Lingchuang Fund Management, Xiangjiang Liyuan Investment
- Angel, Jan 9, 2018 — Goldport Capital, CMAF, Jiahe Investment Management

## Investors

- Goldport Capital (https://capitalatlas.ai/funds/goldport-capital) — Angel
- CMAF (https://capitalatlas.ai/funds/cmaf) — Angel
- Jiahe Investment Management (https://capitalatlas.ai/funds/jiahe-investment-management) — Angel
- CAS Investment Management (https://capitalatlas.ai/funds/cas-investment-management) — Series B
- Xiaoxiang Capital Group — Series B
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series B
- Huajin Lingchuang Fund Management (https://capitalatlas.ai/funds/huajin-lingchuang-fund-management) — Series B
- Xiangjiang Liyuan Investment (https://capitalatlas.ai/funds/xiangjiang-liyuan-investment) — Series B